Journal of alternative and complementary medicine (New York, N.Y.),2013年19(6):492-500 ISSN：1075-5535
[Guo, Hao] Tianjin Univ Tradit Chinese Med, Minist Educ, Key Lab Pharmacol Tradit Chinese Med Formulae, Tianjin, Peoples R China.;[Wang, Xue-Mei; Wang, Lin-Lin; Fu, Hong; Li, Wei-Wei] Peking Univ, Hosp 1, Inst Integrated Chinese & Western Med, Beijing 100034, Peoples R China.;[Wang, Xue-Mei] Peking Univ, Hosp 1, Inst Integrated Chinese & Western Med, 8 Xishiku St, Beijing 100034, Peoples R China.;[Li, Hong-Hao] Hunan Agr Univ, Lib Hunan Agr Univ, Changsha, Hunan, Peoples R China.
[Wang, Xue-Mei] Peking Univ, Hosp 1, Inst Integrated Chinese & Western Med, 8 Xishiku St, Beijing 100034, Peoples R China.
PURPOSE: Diabetes mellitus with coronary heart disease (DM with CHD) poses a health challenge to people in China and elsewhere in the world. In Traditional Chinese Medicine (TCM), DM with CHD is classified as a type of disease called Xiaoke and Xiongbi. In Asia, TCM has been used to treat Xiaoke and Xiongbi conditions for centuries, especially in China. In this study, it was evaluated whether integrated strategies incorporating both TCM and Western medicines (iTCWM) could improve the curative efficacy of DM with CHD. METHODS: An extensive search for randomized clinical trials (RCTs) published up to November 2011 in either English or Chinese about iTCWM for DM with CHD was conducted. All listings in PubMed, EMBASE, the Cochrane Library, CBM, CNKI, VIP, and the Wanfang database were included in the literature search. The quality of each trial was assessed using the Cochrane Reviewers' Handbook 5.0. Data analysis was performed by the RevMan 5.0 provided by the Cochrane Collaboration. RESULTS: After an initial selection of 207 articles, 21 RCTs and quasi-RCTs were ultimately included in the analysis for this study. All of these trials were conducted in China and published in Chinese journals. The methodological quality of the trials was low in most studies. Selection bias and measurement bias were common in all of the studies. A meta-analysis was not conducted, due to the poor quality of the available studies. CONCLUSIONS: The current state of the literature regarding the utility of iTCWM for the treatment of DM with CHD is inadequate. The poor quality of the available trials makes it difficult to draw any conclusions regarding the efficacy of iTCWM for the treatment of DM with CHD. This study highlights the paucity of reliable clinical evidence for iTCWM and the need for higher quality RCTs to be conducted in the future.